Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2022

Open Access 01-12-2022 | Breast Cancer | Research

Mechanisms of miR-3189-3p-mediated inhibition of c-MYC translation in triple negative breast cancer

Authors: Cecilia Vittori, Duane Jeansonne, Hassan Yousefi, Celeste Faia, Zhen Lin, Krzysztof Reiss, Francesca Peruzzi

Published in: Cancer Cell International | Issue 1/2022

Login to get access

Abstract

Background

Triple negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by the lack of estrogen receptor, progesterone receptor, and HER2. Our lab previously characterized miR-3189-3p as a microRNA with potent anti-cancer activity against glioblastoma. Here, we hypothesized a similar activity in TNBC cells. As miR-3189-3p is predicted to target a variety of RNA binding proteins, we further hypothesized an inhibitory effect of this miRNA on protein synthesis.

Methods

MDA-MB-231 and MDA-MB-468 cells were used to investigate the effect of miR-3189-3p on cell proliferation, migration, and invasion. TGCA database was used to analyze the expression of miR-3189-3p, c-MYC, 4EPB1, and eIF4E in breast cancer. Western blotting and RT-qPCR assays were used to assess the expression of selected proteins and RNAs after transfections.

Results

Although c-MYC is not a predicted gene target for miR-3189-3p, we discovered that c-MYC protein is downregulated in miRNA-treated TNBC cells. We found that the downregulation of c-MYC by miR-3189-3p occurs in both normal growth conditions and in the absence of serum. The mechanism involved the direct inhibition of eIF4EBP1 by miR-3189-3p. Additionally, we found that miR-3189-3p could negatively affect cap-independent translation mediated by internal ribosome entry sites (IRES) or by m6A. Finally, miR-3189-3p sensitized TNBC cells to doxorubicin.

Conclusion

Overall, results indicated that miR-3189-3p exerts its anti-tumor activity through targeting translational regulatory proteins leading to an impairment in c-MYC translation, and possibly other oncogenic factors, suggesting that miR-3189-3p, alone or in combination, could be a valuable therapeutic approach against a malignancy with few treatment options.
Literature
1.
Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, Ruddy K, Tsang J, Cardoso F. Breast cancer. Nat Rev Dis Primers. 2019;5(1):66.PubMedCrossRef
2.
Jia LY, Shanmugam MK, Sethi G, Bishayee A. Potential role of targeted therapies in the treatment of triple-negative breast cancer. Anticancer Drugs. 2016;27(3):147–55.PubMedCrossRef
3.
Kawaji H, Kubo M, Yamashita N, Yamamoto H, Kai M, Kajihara A, Yamada M, Kurata K, Kaneshiro K, Harada Y. Comprehensive molecular profiling broadens treatment options for breast cancer patients. Cancer Med. 2020;10(2):529–39.PubMedPubMedCentralCrossRef
4.
Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Hegg R, Im S-A, Shaw Wright G. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108–21.PubMedCrossRef
5.
Castellvi J, Garcia A, Rojo F, Ruiz-Marcellan C, Gil A, Baselga J, Ramon y Cajal S. Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer. 2006;107(8):1801–11.PubMedCrossRef
6.
Musa J, Orth M, Dallmayer M, Baldauf M, Pardo C, Rotblat B, Kirchner T, Leprivier G, Grünewald T. Eukaryotic initiation factor 4E-binding protein 1 (4E-BP1): a master regulator of mRNA translation involved in tumorigenesis. Oncogene. 2016;35(36):4675–88.PubMedCrossRef
7.
8.
Batool A, Aashaq S, Andrabi KI. Reappraisal to the study of 4E-BP1 as an mTOR substrate—a normative critique. Eur J Cell Biol. 2017;96(4):325–36.PubMedCrossRef
9.
Braunstein S, Karpisheva K, Pola C, Goldberg J, Hochman T, Yee H, Cangiarella J, Arju R, Formenti SC, Schneider RJ. A hypoxia-controlled cap-dependent to cap-independent translation switch in breast cancer. Mol Cell. 2007;28(3):501–12.PubMedCrossRef
10.
Chao M-W, Wang L-T, Lai C-Y, Yang X-M, Cheng Y-W, Lee K-H, Pan S-L, Teng C-M. eIF4E binding protein 1 expression is associated with clinical survival outcomes in colorectal cancer. Oncotarget. 2015;6(27):24092.PubMedPubMedCentralCrossRef
11.
Kremer CL, Klein RR, Mendelson J, Browne W, Samadzedeh LK, Vanpatten K, Highstrom L, Pestano GA, Nagle RB. Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate. 2006;66(11):1203–12.PubMedCrossRef
12.
Sulaiman A, McGarry S, Lam KM, El-Sahli S, Chambers J, Kaczmarek S, Li L, Addison C, Dimitroulakos J, Arnaout A. Co-inhibition of mTORC1, HDAC and ESR1α retards the growth of triple-negative breast cancer and suppresses cancer stem cells. Cell Death Dis. 2018;9(8):1–14.CrossRef
13.
Camarda R, Zhou AY, Kohnz RA, Balakrishnan S, Mahieu C, Anderton B, Eyob H, Kajimura S, Tward A, Krings G. Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer. Nat Med. 2016;22(4):427–32.PubMedPubMedCentralCrossRef
14.
15.
Horiuchi D, Kusdra L, Huskey NE, Chandriani S, Lenburg ME, Gonzalez-Angulo AM, Creasman KJ, Bazarov AV, Smyth JW, Davis SE. MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. J Exp Med. 2012;209(4):679–96.PubMedPubMedCentralCrossRef
16.
Persson H, Kvist A, Rego N, Staaf J, Vallon-Christersson J, Luts L, Loman N, Jonsson G, Naya H, Hoglund M, et al. Identification of new microRNAs in paired normal and tumor breast tissue suggests a dual role for the ERBB2/Her2 gene. Cancer Res. 2011;71(1):78–86.PubMedCrossRef
17.
Jeansonne D, DeLuca M, Marrero L, Lassak A, Pacifici M, Wyczechowska D, Wilk A, Reiss K, Peruzzi F. Anti-tumoral effects of miR-3189-3p in glioblastoma. J Biol Chem. 2015;290(13):8067–80.PubMedPubMedCentralCrossRef
18.
19.
Curtis C, Shah SP, Chin S-F, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486(7403):346–52.PubMedPubMedCentralCrossRef
20.
Pereira B, Chin S-F, Rueda OM, Vollan H-KM, Provenzano E, Bardwell HA, Pugh M, Jones L, Russell R, Sammut S-J. The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes. Nat Commun. 2016;7(1):1–16.
21.
Koboldt D, Fulton R, McLellan M, Schmidt H, Kalicki-Veizer J, McMichael J, Fulton L, Dooling D, Ding L, Mardis E. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70.CrossRef
22.
23.
Rousseau D, Gingras A-C, Pause A, Sonenberg N. The eIF4E-binding proteins 1 and 2 are negative regulators of cell growth. Oncogene. 1996;13(11):2415–20.PubMed
24.
Godet A-C, David F, Hantelys F, Tatin F, Lacazette E, Garmy-Susini B, Prats A-C. IRES trans-acting factors, key actors of the stress response. Int J Mol Sci. 2019;20(4):924.PubMedCentralCrossRef
25.
Licursi M, Komatsu Y, Pongnopparat T, Hirasawa K. Promotion of viral internal ribosomal entry site-mediated translation under amino acid starvation. J Gen Virol. 2012;93(5):951–62.PubMedCrossRef
26.
27.
Nanbru C, Lafon I, Audigier S, Gensac M-C, Vagner S, Huez G, Prats A-C. Alternative translation of the proto-oncogene c-mycby an internal ribosome entry site. J Biol Chem. 1997;272(51):32061–6.PubMedCrossRef
28.
Stoneley M, Willis AE. Cellular internal ribosome entry segments: structures, trans-acting factors and regulation of gene expression. Oncogene. 2004;23(18):3200–7.PubMedCrossRef
29.
Créancier L, Mercier P, Prats A-C, Morello D. c-myc Internal ribosome entry site activity is developmentally controlled and subjected to a strong translational repression in adult transgenic mice. Mol Cell Biol. 2001;21(5):1833–40.PubMedPubMedCentralCrossRef
30.
Bian Y, Guo J, Qiao L, Sun X. miR-3189–3p mimics enhance the effects of S100A4 siRNA on the inhibition of proliferation and migration of gastric cancer cells by targeting CFL2. Int J Mol Sci. 2018;19(1):236.PubMedCentralCrossRef
31.
Jones MF, Li XL, Subramanian M, Shabalina SA, Hara T, Zhu Y, Huang J, Yang Y, Wakefield LM, Prasanth KV, et al. Growth differentiation factor-15 encodes a novel microRNA 3189 that functions as a potent regulator of cell death. Cell Death Differ. 2015;22(10):1641–53.PubMedPubMedCentralCrossRef
32.
Sadhukhan D, Das G, Biswas A, Ghosh S, Das SK, Ray K, Ray J. Evaluation of FGF 20 variants for susceptibility to Parkinson’s disease in Eastern Indians. Neurosci Lett. 2018;675:68–73.PubMedCrossRef
33.
Zhang Y, Zheng H, Li B. Circ_0110251 overexpression alleviates IL-1beta-induced chondrocyte apoptosis and extracellular matrix degradation by regulating miR-3189–3p/SPRY1 axis in osteoarthritis. Autoimmunity. 2022;55(3):168–78.PubMedCrossRef
34.
Bian Y, Guo J, Qiao L, Sun X. miR-3189-3p mimics enhance the effects of S100A4 siRNA on the inhibition of proliferation and migration of gastric cancer cells by targeting CFL2. Int J Mol Sci. 2018;19(1):236.PubMedCentralCrossRef
35.
Scheffer D, Kulcsar G, Nagyeri G, Kiss-Merki M, Rekasi Z, Maloy M, Czompoly T. Active mixture of serum-circulating small molecules selectively inhibits proliferation and triggers apoptosis in cancer cells via induction of ER stress. Cell Signal. 2020;65: 109426.PubMedCrossRef
36.
37.
Fallah Y, Brundage J, Allegakoen P, Shajahan-Haq AN. MYC-driven pathways in breast cancer subtypes. Biomolecules. 2017;7(3):53.PubMedCentralCrossRef
38.
Hsieh AL, Walton ZE, Altman BJ, Stine ZE, Dang CV: MYC and metabolism on the path to cancer. In: Seminars in cell & developmental biology: 2015: Elsevier; 2015: 11–21.
39.
40.
Deng C, Lipstein MR, Scotto L, Jirau Serrano XO, Mangone MA, Li S, Vendome J, Hao Y, Xu X, Deng S-X. Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies. Blood. 2017;129(1):88–99.PubMedPubMedCentralCrossRef
41.
Villalonga P, de Mattos SF, Ridley AJ. RhoE inhibits 4E-BP1 phosphorylation and eIF4E function impairing cap-dependent translation. J Biol Chem. 2009;284(51):35287–96.PubMedPubMedCentralCrossRef
42.
Alain T, Morita M, Fonseca BD, Yanagiya A, Siddiqui N, Bhat M, Zammit D, Marcus V, Metrakos P, Voyer L-A. eIF4E/4E-BP ratio predicts the efficacy of mTOR targeted therapies. Can Res. 2012;72(24):6468–76.CrossRef
43.
Hsu H-S, Lin M-H, Jang Y-H, Kuo T-T, Liu C-C, Cheng T-H. The 4E-BP1/eIF4E ratio is a determinant for rapamycin response in esophageal cancer cells. J Thorac Cardiovasc Surg. 2015;149(1):378–85.PubMedCrossRef
44.
45.
Beretta L, Gingras AC, Svitkin YV, Hall MN, Sonenberg N. Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation. EMBO J. 1996;15(3):658–64.PubMedPubMedCentralCrossRef
46.
Constantinou C, Clemens MJ. Regulation of the phosphorylation and integrity of protein synthesis initiation factor eIF4GI and the translational repressor 4E-BP1 by p53. Oncogene. 2005;24(30):4839–50.PubMedCrossRef
47.
Vaklavas C, Grizzle WE, Choi H, Meng Z, Zinn KR, Shrestha K, Blume SW. IRES inhibition induces terminal differentiation and synchronized death in triple-negative breast cancer and glioblastoma cells. Tumor Biology. 2016;37(10):13247–64.PubMedCrossRef
48.
Sriram A, Bohlen J, Teleman AA. Translation acrobatics: how cancer cells exploit alternate modes of translational initiation. EMBO Rep. 2018;19(10): e45947.PubMedPubMedCentralCrossRef
49.
50.
51.
Yang D-D, Chen Z-H, Yu K, Lu J-H, Wu Q-N, Wang Y, Ju H-Q, Xu R-H, Liu Z-X, Zeng Z-L. METTL3 promotes the progression of gastric cancer via targeting the MYC pathway. Front Oncol. 2020;10:115.PubMedPubMedCentralCrossRef
52.
Yuan Y, Du Y, Wang L, Liu X. The M6A methyltransferase METTL3 promotes the development and progression of prostate carcinoma via mediating MYC methylation. J Cancer. 2020;11(12):3588.PubMedPubMedCentralCrossRef
Metadata
Title
Mechanisms of miR-3189-3p-mediated inhibition of c-MYC translation in triple negative breast cancer
Authors
Cecilia Vittori
Duane Jeansonne
Hassan Yousefi
Celeste Faia
Zhen Lin
Krzysztof Reiss
Francesca Peruzzi
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2022
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-022-02620-z

Other articles of this Issue 1/2022

Cancer Cell International 1/2022 Go to the issue

Retraction Note

Retraction Note: LncRNA TUBA4B functions as a competitive endogenous RNA to inhibit gastric cancer progression by elevating PTEN via sponging miR-214 and miR-216a/b

Research

Prediction of hepatocellular carcinoma prognosis and immunotherapeutic effects based on tryptophan metabolism-related genes

Research

Etomoxir, a carnitine palmitoyltransferase 1 inhibitor, combined with temozolomide reduces stemness and invasiveness in patient-derived glioblastoma tumorspheres

Review

Interactions of melatonin with various signaling pathways: implications for cancer therapy

Review

The molecular biology and therapeutic potential of Nrf2 in leukemia

Research

Correlation of the prognostic value of FNDC4 in glioblastoma with macrophage polarization
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits